vTv Therapeutics
VTVT
20 hedge funds and large institutions have $7.34M invested in vTv Therapeutics in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
19% more capital invested
Capital invested by funds: $6.15M → $7.34M (+$1.19M)
7.99% more ownership
Funds ownership: 14.33% → 22.32% (+8%)
5% more funds holding
Funds holding: 19 → 20 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$282K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$171K |
| 4 |
BlackRock
New York
|
+$60.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$216K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$55K |
| 3 |
JP Morgan Chase
New York
|
-$35 |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$18 |
| 5 |
TWP
Triad Wealth Partners
Lawrence,
Kansas
|
-$18 |
VTVT Hedge Fund Activity: Q3 2024 in Review
20 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2024, worth a combined $7.34M — up 19% from $6.15M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTVT positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $2.96M. The largest seller was Millennium Management, exiting entirely with an estimated $216K sold.
- 20 institutional investors held vTv Therapeutics (VTVT) as of Q3 2024, up from 19 in Q2 2024.
- Funds reported $7.34M of vTv Therapeutics stock for Q3 2024, up 19% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q3 2024 and 4 closed out, a net change of +1 holder.
- The largest vTv Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $2.96M added.
- The largest vTv Therapeutics seller in Q3 2024 was Millennium Management, an estimated $216K sold.
Based on aggregated 13F filings for Q3 2024.